Physician profile
Maxime Debrosse
NPI 1750649703
$2,444.54
in general payments reported to CMS, 2019-2025
10 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 78% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $36.93 · 2022: $116 · 2023: $295 · 2024: $205 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,273 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.09 |
| Travel and Lodging | $873.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,075.13 | 2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Spr Therapeutics, INC | $436.74 | 2022-2025 | Sprint Pns System |
| Abbott Laboratories | $288.04 | 2019-2025 | Proclaim, Freestyle Libre 2 |
| Globus Medical, INC. | $217.96 | 2025 | Senza |
| Neurocrine Biosciences, INC. | $124.97 | 2024 | Ingrezza |
| Nevro Corp. | $84.08 | 2019 | |
| Kerecis Limited | $82.76 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Abbvie INC. | $52.99 | 2022-2023 | Ubrelvy |
| Bioventus LLC | $44.94 | 2025 | Xcell |
| Medtronic, INC. | $36.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxime Debrosse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.